Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Arcturus Therapeutics has a “Moderate Buy” consensus rating from 11 analysts, with six buys, one strong buy, three holds, and one sell. The average 12-month price target is $24.25.
• ARCT opened at $8.23, compared with a 12-month range of $5.50 to $24.17, while its market capitalization stands at approximately $233.9 million.
• The company reported a quarterly loss of $0.84 per share, better than the $1.00 consensus estimate, but revenue of $2.96 million fell short of expectations. Institutional investors own 94.54% of outstanding shares.

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) has earned a consensus rating of "Moderate Buy" from the eleven ratings firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, three have given a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $24.25.

A number of research firms have weighed in on ARCT. Wall Street Zen raised shares of Arcturus Therapeutics from a "strong sell" rating to a "sell" rating in a research report on Sunday, August 9th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Arcturus Therapeutics in a research report on Friday, July 17th.

Arcturus Therapeutics Price Performance

Arcturus Therapeutics stock opened at $8.23 on Monday. The stock has a market cap of $233.90 million, a PE ratio of -2.49 and a beta of 2.39. Arcturus Therapeutics has a 12-month low of $5.50 and a 12-month high of $24.17. The business's 50-day moving average price is $6.77 and its two-hundred day moving average price is $7.40.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.84) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.16. Arcturus Therapeutics had a negative return on equity of 46.54% and a negative net margin of 317.62%.The company had revenue of $2.96 million during the quarter, compared to analysts' expectations of $3.11 million. As a group, analysts expect that Arcturus Therapeutics will post -3.48 earnings per share for the current year.

Institutional Trading of Arcturus Therapeutics

Hedge funds have recently modified their holdings of the stock. Osaic Holdings Inc. raised its holdings in shares of Arcturus Therapeutics by 51.8% during the second quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 738 shares during the period. BNP Paribas Financial Markets grew its stake in shares of Arcturus Therapeutics by 163.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company's stock valued at $54,000 after buying an additional 2,586 shares during the period. Mercer Global Advisors Inc. ADV bought a new stake in Arcturus Therapeutics in the 4th quarter valued at about $64,000. Intech Investment Management LLC bought a new stake in Arcturus Therapeutics in the 4th quarter valued at about $70,000. Finally, CANADA LIFE ASSURANCE Co raised its stake in Arcturus Therapeutics by 65.1% during the 4th quarter. CANADA LIFE ASSURANCE Co now owns 12,009 shares of the biotechnology company's stock worth $73,000 after buying an additional 4,737 shares during the period. Institutional investors own 94.54% of the company's stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus's approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company's pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source